SUN PHARMA ADV.RES.CO.LTD Financial Ratios
SPARC · Healthcare · Current price ₹187.81
P/E ratio
3.9x
P/B ratio
4.7x
ROE
116.2%
ROCE
83.6%
Debt / Equity
0.42
Dividend yield
—
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 3.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 4.7x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 116.2% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 83.6% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.42 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with SUN PHARMA ADV.RES.CO.LTD's latest numbers.
SUN PHARMA ADV.RES.CO.LTD profitability
SUN PHARMA ADV.RES.CO.LTD generates a return on equity of 116.2% and a return on capital employed of 83.6%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.42 and a P/E of 3.9x, SUN PHARMA ADV.RES.CO.LTD is conservatively financed. Our overall business-quality score for the company is 7.0 / 10.
Understand the ratios
More on SUN PHARMA ADV.RES.CO.LTD
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.